Urologix launches transurethral thermo-ablation system:
This article was originally published in Clinica
Urologix (UK) has launched its T3 targeted transurethral thermo-ablation system in Europe. The T3 microwave catheters are for treating benign prostatic hyperplasia. Clinical studies in the US and UK have shown that the system avoids some of the common complications associated with transurethral prostatic resection.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.